A RANDOMIZED PHASE II STUDY OF NIVOLUMAB VERSUS NIVOLUMAB AND BMS-986016 (RELATLIMAB) AS MAINTENANCE TREATMENT AFTER FIRST-LINE TREATMENT WITH PLATINUM-GEMCITABINE-NIVOLUMAB FOR PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA (REMAIN)

Registry ID

NRG-HN011

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

NRG ONCOLOGY

Last update

2024-03-21

Conditions

• EPSTEIN-BARR VIRUS (EBV) INFECTION
• NASOPHARYNGEAL CARCINOMA

Related clinical trials

• A PHASE 2 STUDY USING CHEMOIMMUNOTHERAPY WITH GEMCITABINE, CISPLATIN AND NIVOLUMAB IN NEWLY DIAGNOSES NASOPHARYNGEAL CARCINOMA (NPC)
• TRANSPARENT: A SINGLE-ARM STUDY OF TORIPALIMAB IN COMBINATION WITH CISPLATIN AND GEMCITABINE IN RECURRENT METASTATIC NASOPHARYNGEAL CARCINOMA SYSTEMIC TREATMENT NAÏVE PARTICIPANTS
• A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER PHASE III STUDY OF PENPULIMAB (AK105) COMBINED WITH CHEMOTHERAPY VERSUS PLACEBO COMBINED WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
• A PHASE I/II OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF EPSTEIN-BARR VIRUS SPECIFIC T-CELL LINES FOR THE TREATMENT OF EBV INFECTION OR EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
• RANDOMIZED PHASE II AND PHASE III STUDIES OF INDIVIDUALIZED TREATMENT FOR NASOPHARYNGEAL CARCINOMA BASED ON BIOMARKER EPSTEIN BARR VIRUS (EBV) DEOXYRIBONUCLEIC ACID

View on source registry